The company said, “For fiscal year 2025, the Company expects revenue in the range of $165 million to $175 million. This guidance assumes a high single-digit millions decline in our Americas academic revenue due to anticipated NIH funding pressures, no expected effect from U.S. export controls and limited impact from tariffs.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LAB:
- Standard Biotools Inc (LAB) Q4 Earnings Cheat Sheet
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Standard BioTools Reports 2024 Revenue Achievements and Plans
- Standard BioTools reports preliminary Q4 revenue $46.5M, consensus $43.03M
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue